17-AAG is a synthetic derivative of geldanamycin and acts as an anti-tumor agent. 17-AAG binds specifically to heat shock protein Hsp90. Hsp90 is a protein chaperone that binds to client proteins. Client proteins include important cancer– relevant targets such as mutated p53, Her2, Bcr-Abl, Raf-1, Akt and others. 17-AAG disrupts the Hsp-900 client protein complexes and leads to the degredation of the client proteins.